Brief: Sino Biopharmaceutical Says NMPA Acceptance Of NDA For Rovadicitinib (Tq05105)
15/07/2024 11:10
July 15 (Reuters) - Sino Biopharmaceutical 1177.HK :
* NMPA CHINA ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY
1
INNVOATIVE DRUG ROVADICITINIB TABLET \"ROVADICITINIB (TQ05105)
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up